Evoke Pharma

Evoke Pharma issues topline results from EVK-001 phase III trial

Thursday, July 21, 2016

Evoke Pharma, a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, has announced topline results from its phase III clinical trial of EVK-001 in female patients with symptomatic diabetic gastroparesis. In this study, EVK-001, the company’s patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adult women, did not achieve its primary endpoint of symptom improvement at Week 4.

[Read More]